GANTRISIN PEDIATRIC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Gantrisin Pediatric, and when can generic versions of Gantrisin Pediatric launch?
Gantrisin Pediatric is a drug marketed by Roche and is included in one NDA.
The generic ingredient in GANTRISIN PEDIATRIC is sulfisoxazole acetyl. There are three drug master file entries for this compound. Additional details are available on the sulfisoxazole acetyl profile page.
Summary for GANTRISIN PEDIATRIC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 50 |
| Patent Applications: | 1,689 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | GANTRISIN PEDIATRIC at DailyMed |
US Patents and Regulatory Information for GANTRISIN PEDIATRIC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Roche | GANTRISIN PEDIATRIC | sulfisoxazole acetyl | SUSPENSION;ORAL | 009182-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
